The FDA has granted Orphan Drug designation to ATX01 (proprietary topical amitriptyline; AlgoTherapeutix) for the treatment of erythromelalgia. The Food and Drug Administration (FDA) has granted ...
The global erythromelalgia treatment market reach USD 1.98 Billion in 2022 and is expected to exhibit a CAGR of 5.3% over the forecast period 2023 to 2032 PUNE ...
SURESNES, France--(BUSINESS WIRE)--European biotech AlgoTherapeutix, an innovator in complex pain therapy, today announces the U.S. Food and Drug Administration (FDA) has granted ATX01 (proprietary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback